Register for free to
view the full innovation profile.
PAW, supported by AuNPs and hot electron transfer, breaks the HBs to create energetic and antioxidant properties which can eliminate progression of neurodegenerative diseases.
About
The treatment and care of dementia has become an urgent healthy issue for most countries. Alzheimer's disease (AD),the most common cause of dementia, characterized by memory impairment followed by decline of many cognitive domains resulting in dysfunction of activities of daily life. Amyloid and tau which are main components of senile plaques and neurofibril tangles respectively are considered to play important roles in pathophysiology of AD. To date, there are only a few drugs are approved by Food and Drug Administration (FDA), USA, for AD therapy. These drugs are mainly beneficial for AD patients in cognitive function. The Plasmon-activated water (PAW) is an innovative invention that possesses numerous advantages compared to conventional deionized water (DIW). By letting DIW flow through supported gold nanoparticles (AuNPs) under resonant illumination, effective hot electron transfer breaks the hydrogen bonds (HBs) and thus makes PAW more active in reactions including their ability to scavenge free hydroxyl and 2,2-diphenyl-1-picrylhydrazyl radicals and to effectively reduce NO release from lipopolysaccharide (LPS)-induced inflammatory cells. Therefore, PAW holds a huge potential for the treatment to eliminate progression of neurodegenerative diseases.
Key Benefits
We already have patents granted including USA and Taiwan, pending EU in Japan and China.
Applications
PAW will target on general health care, anti-inflammatory, neurodegenerative diseases, dementia, Alzheimer’s disease, Parkinson disease, neuronal disorder, cancer, anti-tumor, depression and Autism.